Thermo Fisher Scientific is buying drug-ingredients maker Patheon for $7.2 billion
In a statement Monday, Thermo Fisher said it would acquire all outstanding Patheon shares for $35 apiece in cash, 35% higher than where the stock closed Friday.
The deal's value includes approximately $2 billion of net debt.
Patheon is a contract development and manufacturing organization, or CDMO, and contracts with other companies to develop drugs. By acquiring the company, Thermo Fisher aims to enter what it describes as a high-growth market that helps companies deliver drugs to the market quicker and at lower costs.
"Over the past several years, we have increased our capabilities to become a leading CDMO provider in a highly fragmented market," Patheon CEO James Mullen said in a statement. "We are confident that our combined offerings and Thermo Fisher's proven track record of disciplined M&A and successful integrations will take our business to the next level."
Thermo Fisher was formed in 2006 after a merger by Thermo Electron and Fisher Scientific.
Goldman Sachs is Thermo Fisher's financial adviser, while Morgan Stanley is working with Patheon.
The deal is expected to close by the end of 2017.
- I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
- Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
- Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
- Audi to hike vehicle prices by up to 2% from June
- Kotak Mahindra Bank shares tank 13%; mcap erodes by ₹37,721 crore post RBI action
- Rupee falls 6 paise to 83.39 against US dollar in early trade
- Markets decline in early trade; Kotak Mahindra Bank tanks over 12%
- An Ambani disruption in OTT: At just ₹1 per day, you can now enjoy ad-free content on JioCinema